Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

Q: My doctor is suggesting that I try taking one of those new weight loss drugs -- off-label -- to help me cut down on my alcohol consumption. Does this make any sense? -- Pat R., Ann Arbor, Michigan ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...